Kinsale Capital Grp

Kinsale did $1.9 billion in annual revenue with just 457 employees, and the market still only gives it a $9 billion cap.

If you own Kinsale, you own a small company betting it can keep pricing oddball business better than everyone else.

knsl

financials mid cap updated feb 27, 2026
$371.32
market cap ~$9B · 52-week range $341–$422
xvary composite: 61 / 100 · average
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
Kinsale sells hard-to-price business insurance through independent brokers in all 50 states.
how it gets paid
Last year Kinsale Capital Grp made $1.9B in revenue. Excess and General Casualty was the main engine at $0.50B, or 26% of sales.
why it's growing
Revenue grew 18.0% last year. $52.3 million of net investment income mattered most because it rose nearly 25% and gave results a second engine beyond underwriting.
what just happened
Kinsale reported $5.81 in quarterly operating profit per share, ahead of the $5.20 estimate.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
75/100 earnings predictability — reasonably predictable
19.0x trailing p/e — priced about right
0.3% dividend yield — cash in your pocket every quarter
24.9% return on capital — every dollar works hard here
xvary composite: 61/100 — average
What they do
Kinsale sells hard-to-price business insurance through independent brokers in all 50 states.
Kinsale lives in specialty insurance (hard-to-price coverage for weird commercial risks → fewer competitors → better prices). You want the company that says no a lot, because strict underwriting (screening risks before writing policies → fewer bad claims → steadier profits) helped keep premiums earned growing more than 15% while net investment income rose 25% to $52.3 million. That discipline shows up in a 24.9% return on capital.
financials mid-cap insurance underwriting specialty-lines
How they make money
$1.9B annual revenue · their business grew +18.0% last year
Excess and General Casualty
$0.50B
Commercial Property
$0.48B
Construction
$0.46B
Small Business and Other Commercial Lines
$0.46B
The products that matter
writes specialty p&c policies
specialty property and casualty insurance
$1.9B · +18.0% growth
it is the entire disclosed revenue base at $1.9B. If underwriting stumbles, there is no other segment here to bail out the story.
entire revenue base
Key numbers
$22.70
fy2027 eps est
$1.9B
fy rev est
SEC filings point to roughly $1.9B in annual sales.
19.0x
trailing p/e
0.3%
dividend yield
Financial health
B++
strength
  • balance sheet grade B++ — above average financial health
  • risk rank 3 — safer than 50% of stocks
  • price stability 40 / 100
  • return on equity 14% — $0.14 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market

You invested $10,000 in KNSL 3 years ago → it's now worth $12,520.

The index would have given you $13,880.

source: institutional data · total return
What just happened
beat estimates
Kinsale reported $5.81 in quarterly operating profit per share, ahead of the $5.20 estimate.
The biggest driver was net investment income, which climbed nearly 25% vs. prior year to $52.3 million. The company also grew net premiums earned by more than 15% while keeping underwriting tight.
$1.4B
revenue
$5.81
profit per share
$52.3M
investment income
the number that mattered
$52.3 million of net investment income mattered most because it rose nearly 25% and gave results a second engine beyond underwriting.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

the #1 risk is underwriting deterioration in specialty property and casualty insurance.

med
underwriting mistakes hit the whole story
KNSL shows one disclosed $1.9B revenue engine. There is no giant second segment here to hide a bad claims stretch.
If underwriting discipline slips, both earnings quality and the premium multiple take the hit.
med
growth slows, then the multiple follows
Revenue grew 18.0% from last year. That pace is a big part of why 19.0x trailing earnings feels acceptable.
If growth falls below that without better margin evidence, the market can price this like a normal insurer fast.
med
the stock is less stable than the business
Price stability is only 40 / 100. That means sentiment can move faster than the operating numbers.
If investors start questioning reserve quality or claims assumptions, you feel it in the stock before you see it in the annual revenue line.
med
there is almost no income cushion
The dividend yield is 0.3%. You are not collecting much cash while you wait for the thesis to prove itself.
If shares stall for a while, patience has to come from conviction, not income.
Great underwriting can still be a bad trade if you pay for perfection. Your risk here is the stock, not just the business.
source: institutional data · regulatory filings · risk analysis
Pay attention to
growth
18.0% revenue growth
If growth stays near the high teens, the compounding case holds together. If it fades fast, this starts looking like an ordinary insurer with an above-ordinary valuation.
valuation
19.0x trailing p/e
Cheap enough if quality holds. Rich enough if growth disappoints. That narrow middle is the setup.
institutional flow
275 buyers vs. 282 sellers
Basically balanced, with a slight lean negative. You want conviction to improve, not just avoid getting worse.
range check
$341–$422 trading band
The stock sits in the lower half of its 52-week range. A move higher needs fresh proof. A move lower says the market still does not buy the story.
Analyst rankings
earnings predictability
75 / 100
in human-speak, analysts see this as more dependable than most mid caps, but not clockwork.
risk rank
3
middle of the safety pack — less fragile than the market's rough edges, less defensive than the leaders.
price stability
40 / 100
the operating business may be disciplined. the stock still trades like investors are debating the durability of that discipline.
source: institutional data
Institutional activity

275 buyers vs. 282 sellers in 3q2025. total institutional holdings: 19.7M shares.

source: institutional data
Price targets
3-5 year target range
$308 $626
$371 current price
$467 target midpoint · +26% from current · 3-5yr high: $650 (+75% · 15% ann'l return)
source: institutional data · analyst targets

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
KNSL
xvary deep dive
knsl
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it